Nicox resubmits NDA for AC-170

Nicox has resubmitted a new drug application for AC-170, its eye drop formulation to treat ocular itching associated with allergic conjunctivitis, according to a company press release.Branded as Zerviate, AC-170 (cetirizine ophthalmic solution 0.24%) was initially submitted in April 2016, but the company received a complete response letter from the FDA in October citing inspection issues with a third-party production facility.

Full Story →